(3S,5S)-Atorvastatin (sodium salt)
(Synonyms: 阿托伐他汀EP杂质C) 目录号 : GC13751
An enantiomer of atorvastatin
Cas No.:1428118-38-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase [1]. Atorvastatin is a synthetic HMG-CoA reductase inhibitor implicated in lowering plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. Atorvastatin also reduces triglyceride levels through an as yet unproven mechanism [2]. In various trials in patients with hypercholesterolaemia, atorvastatin produced greater reductions in total cholesterol, apolipoprotein B, LDL-cholesterol and triglyceride levels. In patients with primary hypercholesterolaemia, atorvastatin in combination with colestipol produced significant reductions in LDL-cholesterol levels and smaller reductions in triglyceride levels than atorvastatin monotherapy [2].
References:
[1] Kocarek T A, Dahn M S, Cai H, et al. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes[J]. Drug Metabolism and Disposition, 2002, 30(12): 1400-1405.
[2] Lea A P, McTavish D. Atorvastatin[J]. Drugs, 1997, 53(5): 828-847.
| Cas No. | 1428118-38-0 | SDF | |
| 别名 | 阿托伐他汀EP杂质C | ||
| 化学名 | 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, monosodium salt | ||
| Canonical SMILES | O=C(C1=C(C(C)C)N(CC[C@H](O)C[C@H](O)CC([O-])=O)C(C2=CC=C(F)C=C2)=C1C3=CC=CC=C3)NC4=CC=CC=C4.[Na+] | ||
| 分子式 | C33H34FN2O5 • Na | 分子量 | 580.6 |
| 溶解度 | ≤0.5mg/ml in ethanol;15mg/ml in DMSO;25mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7224 mL | 8.6118 mL | 17.2236 mL |
| 5 mM | 0.3445 mL | 1.7224 mL | 3.4447 mL |
| 10 mM | 0.1722 mL | 0.8612 mL | 1.7224 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。